Black Diamond Therapeutics, Inc.
BDTX · XNASCIK 1701541fmd_02YAWNMTW6C3H8162GRM6QV6SAManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2018 to Sep 30, 2026, 35 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | – | – | – | 0 | 70 |
| Research and development | 7 | 22 | 48 | 97 | 64 | 59 | 51 | 34 |
| Total operating expenses | 9 | 29 | 70 | 127 | 93 | 86 | 79 | 57 |
| Operating income | (9) | (29) | (70) | (127) | (93) | (86) | (79) | 13 |
| Interest expense | – | 0 | 0 | 0 | – | – | – | – |
| Other non-operating income (expense) | (0) | (6) | 2 | 1 | 4 | 4 | 9 | 10 |
| Income before taxes | – | – | (67) | (126) | (91) | (82) | (70) | 22 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | (67) | (126) | (91) | (82) | (70) | 22 |
| Net income | (9) | (35) | (67) | (126) | (91) | (82) | (70) | 22 |